Cohort Study of the Clinical Course of Macular Diseases in Kagawa

Last updated: March 6, 2018
Sponsor: Kagawa University
Overall Status: Active - Recruiting

Phase

4

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT02321267
H26-035
  • All Genders

Study Summary

Macular diseases often cases severe visual impairment. Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of various macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. The advance in vitrectomy improve visual outcomes in some maculae diseases, including epiretinal membrane (ERM), macular hole (MH), vitreomacular traction syndrome (VMTS).

Patients with such macular diseases are registered and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients who visit Department of Ophthalmology, Kagawa University Hospital withmacular diseases, such as AMD, PCV, RAP, RVO, DME, ERM, MH, VMTS.

  • Patients who are agreed with the participation of this study.

Exclusion

Exclusion Criteria:

Study Design

Total Participants: 1000
Study Start date:
December 01, 2014
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Kagawa University Faculty of Medicine

    Miki, Kagawa 761-0793
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.